

Fiscal 2025 Financial Results

May 12, 2026

Shionogi & Co., Ltd.



SHIONOGI

Agenda

01

Overview of FY2025 Financial Results (P.3-9)

02

FY2026 Financial Forecasts (P.10-16)

03

Toward the Realization of the 2030 Vision (P.17-37)

- Initiatives in core businesses
- Progress in pipeline

04

Shareholder Return (P.38-40)

Overview of FY2025 Financial Results



SHIONOGI

Financial Highlights

- **Revenue and all profit categories exceeded record highs**
 - Revenue and operating profit reached record highs for the fourth consecutive fiscal year
- **Completion of Equity Acquisition in ViiV Healthcare Ltd. (ViiV)*¹**
 - March 31, 2026: ViiV was reclassified as an equity-method affiliate
- **Completion of the Transfer of the Edaravone Business and Establishment of a New U.S. Company for RADICAVA*²**
 - April 1, 2026: All rights to edaravone in major countries and regions were transferred to SHIONOGI*³
 - On the same date, the company commenced business operations

Financial Results (Consolidated)

Revenue and all profit categories increased year on year

(Unit: B yen)

	FY2025			FY2024		Y on Y	
	Forecasts Full year	Results	Achievement (%)	Results	Change (%)	Change	
Revenue	500.0	499.7	99.9	438.3	14.0	61.4	
Operating profit	185.0	166.7	90.1	156.6	6.5	10.1	
Profit before tax	232.0	238.9	103.0	200.8	19.0	38.2	
Profit attributable to owners of parent	188.0	205.2	109.1	170.4	20.4	34.7	
EBITDA*1	206.0	187.7	91.1	179.3	4.7	8.4	

Statement of Profit or Loss (Consolidated)

(Unit: B yen)

	FY2025		FY2024		Y on Y	
	Forecasts Full year	Results	Achievement (%)	Results	Change (%)	Change
Revenue	500.0	499.7	99.9	438.3	14.0	61.4
Cost of Sales	82.0	82.5	100.5	63.8	29.2	18.6
Gross profit	418.0	417.2	99.8	374.4	11.4	42.8
SG&A*1, R&D expenses total	240.0	255.8	106.6	214.7	19.2	41.2
SG&A*1	120.0	133.0	110.8	106.1	25.4	27.0
R&D expenses	120.0	122.8	102.4	108.6	13.1	14.2
Other income & expenses	7.0	5.3	76.4	(3.2)	-	8.5
Operating profit	185.0	166.7	90.1	156.6	6.5	10.1
Finance income & costs	47.0	72.2	153.6	44.1	63.5	28.0
Profit before tax	232.0	238.9	103.0	200.8	19.0	38.2
Profit attributable to owners of parent	188.0	205.2	109.1	170.4	20.4	34.7

Main variation factors (Y on Y)

Revenue

Increase: Royalty income, Prescription drugs, Overseas subsidiaries /export

Cost of Sales

Increase: Sales of TORII

SG&A

Increase: Selling-related expenses in US business TORII's SG&A expenses, PMI costs

R&D expenses

Increase: Former JT Pharmaceuticals Business unit and TORII's R&D expenses

Other income & expenses

Increase: Negative goodwill gain*2 recognized in connection with the M&A of the JT Group pharmaceutical business

Decrease: An impairment loss reflecting the results of clinical trials for products under development

Finance income & costs

Increase: Dividends from ViiV, Foreign exchange gain

Revenue by Segment

(Unit: B yen)

	FY2025		FY2024	Y on Y		
	Forecast Full year	Results	Achievement (%)	Results	Change (%)	Change
Prescription drugs	143.5	123.5	86.0	98.8	25.0	24.7
Overseas subsidiaries/export	61.0	65.0	106.5	59.1	9.9	5.9
Shionogi Inc. (US)	27.2	28.7	105.8	23.4	22.9	5.4
Fetroja	-	27.8	-	20.0	39.5	7.9
Shionogi B.V. (EU)	19.3	20.8	107.8	16.8	23.4	3.9
Fetcroja	-	16.3	-	12.9	26.3	3.4
Shionogi China	5.9	6.2	104.6	8.7	(28.3)	(2.5)
Others	8.6	9.2	107.2	10.2	(9.4)	(1.0)
Contract manufacturing	14.0	15.1	107.6	17.3	(12.7)	(2.2)
OTC and quasi-drug	17.5	15.0	86.0	16.8	(10.5)	(1.8)
Royalty income	261.5	278.6	106.5	244.7	13.9	33.9
HIV franchise	245.0	261.3	106.7	240.4	8.7	20.9
Others	16.5	17.3	104.7	4.3	304.9	13.0
Others	2.5	2.5	101.6	1.7	51.1	0.9
Total	500.0	499.7	99.9	438.3	14.0	61.4

Main variation factors (Y on Y)

Prescription drugs

- Increase: Sales of TORII and Quviviq
- Decrease: Sales of acute respiratory virus infection treatments

Overseas subsidiaries/export

- Increase: Sales of Fetroja and Fetcroja
- Decrease: Sales of China business

Contract manufacturing

- Decrease: Review of externally outsourced manufacturing in preparation for the integration of Shionogi pharma

Royalty income

- Increase: HIV franchise: Solid ViiV sales
- Others
 - Royalty income from Roche
 - Royalty income related to the former JT Pharmaceutical Business Unit

Prescription Drugs in Japan

(Unit: B yen)

	Forecast Full year	FY2025		FY2024		Y on Y	
		Results	Achievement (%)	Results	Change (%)	Change	
Acute Respiratory Virus Infection Treatments	56.0	33.8	60.3	51.8	(34.8)	(18.0)	
Quviviq	2.5	2.6	103.2	0.8	224.1	1.8	
Symproic	6.5	6.1	94.2	5.0	21.2	1.1	
OxyContin franchise	5.3	4.4	83.7	4.3	4.6	0.2	
Others	73.2	76.6	104.5	36.9	107.4	39.6	
TORII*	41.2	40.5	98.4	-	-	40.5	
Total	143.5	123.5	86.0	98.8	25.0	24.7	

Acute respiratory virus infection treatments

- Anti-SARS-CoV-2 drug: Xocova
- Anti-influenza virus drugs: Xofluza, Rapiacta

***TORII**

- ① FY2025 result: September 2025 – March 2026
- ② Change: **+12.7%** (Torii standalone performance)
- September 2024 – March 2025: ¥36.3 billion
- September 2025 – March 2026: ¥40.9 billion

Summary of FY2025 Performance

Driven by growth in key businesses, revenue and all profit metrics reached record highs

—Year-on-year—

Top-line growth excluding the impact of M&A

- **Sales growth of Quviviq following the lifting of prescribing restrictions**
- **Steady growth of cefiderocol in Europe and the U.S.**
- **Strong growth in the HIV business** (driven by LAI*¹ formulations)

Impact of M&A

- Torii +**40.5** B yen
- Royalties related to the former JT pharmaceutical business Unit+**8.3** B yen

Revenue and operating profit reached record highs for the fourth consecutive year

—Versus forecast—

Operating profit shortfall

- **Recognition of expenses related to business investments and U.S. operations**
- **Impairment loss recognized after considering clinical trial results and other relevant factors for development assets**

Outperformance in profit before tax and profit attributable to owners of parent

- **Increase in dividends** driven by ViiV's solid business growth

While investing to build a foundation for growth beyond FY2026, we achieved our forecast for profit attributable to owners of the parent

FY2026 Financial Forecasts



SHIONOGI

Financial Forecast (Consolidated)

Earnings forecast

- Revenue is expected to expand significantly toward the JPY 800 billion target under the 2030 Vision
- Revenue and operating profit are expected to reach record highs for the fifth consecutive year
- Profit attributable to owners of parent is expected to reach a record high for the three consecutive years

(Unit: B yen)

	FY2026		FY2025	Y on Y	
	Forecast	Amount	Result	Change (%)	Change
Revenue	700.0	340.0	499.7	40.1	200.3
Operating profit	220.0	96.0	166.7	32.0	53.3
Profit before tax	220.0	96.0	238.9	(7.9)	(18.9)
Profit attributable to owners of parent	210.0	108.0	205.2	2.4	4.8
EBITDA*1	315.0	152.0	187.7	67.8	127.3

Exchange Rate (Average)		
	FY2026 Forecasts	FY2025 Results
USD(\$) JPY(¥)	153.0	150.67
GBP (£) JPY(¥)	205.0	201.86
EUR(€) JPY(¥)	184.0	174.65

Overview of Financial Forecast

Achieve dramatic revenue growth through M&A

Revenue

- **Domestic prescription pharmaceuticals**
 - Annual sales growth for flagship products such as Torii Pharmaceutical brands and Radicut
 - Stabilization of acute respiratory infection treatments
 - Sales expansion of newly launched products (e.g., Quiviviq, Zurzuvae)
- **Overseas subsidiaries / Exports**
 - Start of RADICAVA sales in the U.S.
 - Further growth of cefiderocol in the U.S. and Europe
- **Royalty income**
 - Continued growth from the HIV franchise
 - Annual royalty income from the former JT pharmaceutical business Unit

Cost of sales

- **Ongoing efforts to reduce costs**
- **One-time costs related to inventory valuation of Edaravone**

SG&A

- **Enhancement of acquired business infrastructure following M&A**
 - Maximization of the value of the RADICAVA business in the U.S.
 - Strengthening domestic business through the integration of Torii
- **Amortization of intangible assets related to M&A, among others**

R&D expenses

- **Selection and focus of development assets based on prioritization**

Financial Impact of Changes in ViiV Healthcare Shareholding

P/L Before Changes

	ViiV-Related Income	Recognition	Line Item
①	HIV Royalty	P/L	Revenue
②	Dividend income (10% stake)	P/L	Financial income
③	Equity method income	—	—



P/L After Changes*1

	ViiV-Related Income	Recognition	Line Item
①	HIV Royalty	P/L	Revenue
②	Dividend income (21.7% stake)	BS	Non-current Assets
③	Equity method income	P/L	Other income & Expenses



① HIV Royalty

Expect continued strong growth next fiscal year driven by ViiV's growth

- Recognized as royalty income in the P/L (**unchanged**)



② Dividend

Not recognized in the P/L, but expected to significantly increase cash flow

Our Stake : 10% → **21.7%**

Toward a more resilient management foundation

(Flexible investment and shareholder returns)



③ Equity method income

Recognize ViiV's net profit in proportion to the equity ownership ratio as equity method income

- Equity method income to be recognized reflects profits after amortization of intangible assets recognized at the time of acquisition
- From FY2027 onward, due to changes in IFRS, it will be recognized below operating profit

Statement of Profit or Loss Forecast (Consolidated)

(Unit: B yen)

	FY2026		FY2025	Y on Y	
	Forecast Full year	Forecast 1H	Result	Change(%)	Change
Revenue	700.0	340.0	499.7	40.1	200.3
Cost of Sales	120.0	64.0	82.5	45.5	37.5
Gross profit	580.0	276.0	417.2	39.0	162.8
SG&A*1, R&D expenses total	395.0	197.0	255.8	54.4	139.2
SG&A	240.0	118.0	133.0	80.4	107.0
R&D expenses	155.0	79.0	122.8	26.2	32.2
Other income & Expenses	35.0	17.0	5.3	554.7	29.7
Operating profit	220.0	96.0	166.7	32.0	53.3
Finance income & costs	-	-	72.2	-	(72.2)
Profit before tax	220.0	96.0	238.9	(7.9)	(18.9)
Profit attributable to owners of parent	210.0	108.0	205.2	2.4	4.8

Revenue Forecast by Segment

(Unit: B yen)

	FY2026		FY2025	Y on Y	
	Forecast Full year	Forecast 1H	Result	Change(%)	Change
Prescription drugs	178.6	79.9	123.5	44.7	55.2
Overseas subsidiaries/export	175.2	85.4	65.0	169.7	110.3
Shionogi Inc. (US)	138.7	68.0	28.7	382.7	110.0
RADICAVA	101.7	51.8	-	-	101.7
Shionogi B.V. (EU)	22.6	11.1	20.8	8.7	1.8
Shionogi China	5.3	2.5	6.2	(15.5)	(1.0)
Others	8.7	3.8	9.2	(6.4)	(0.6)
Contract manufacturing	14.4	7.7	15.1	(4.2)	(0.6)
OTC and quasi-drug	18.8	8.3	15.0	25.0	3.8
Royalty income	310.6	157.7	278.6	11.5	32.0
HIV franchise	276.0	139.1	261.3	5.6	14.7
Others	34.6	18.6	17.3	100.3	17.3
Others	2.3	0.9	2.5	(9.3)	(0.2)
Total	700.0	340.0	499.7	40.1	200.3

Revenue Forecast for Prescription Drugs in Japan

(Unit: B yen)

	FY2026		FY2025	Y on Y	
	Forecast Full year	Forecast 1H	Result	Change(%)	Change
Acute Respiratory Virus Infection drugs	41.6	16.2	33.8	23.0	7.8
Quviviq	6.7	2.9	2.6	157.7	4.1
Zurzuvae	4.0	1.1	0.5	-	3.5
Radicut	7.0	3.5	-	-	7.0
Symproic	6.4	3.1	6.1	5.7	0.3
OxyContin franchise	4.9	2.5	4.4	9.8	0.4
TORII Pharmaceutical products*	77.6	36.8	40.5	91.3	37.0
Other	30.5	13.8	35.5	(14.1)	(5.0)
Prescription drugs	178.6	79.9	123.5	44.7	55.2

Acute respiratory virus infection drugs

- Anti-SARS-CoV-2 drug: Xocova
- Anti-influenza virus drugs: Xofluza, Rapiacta

*TORII Pharmaceutical-related products

- ① FY2025 result: September 2025 – March 2026
 - ② Change: **+13.2%**
- April 2025 – March 2026: ¥68.5 billion

Toward the Realization of the 2030 Vision

- Initiatives in core businesses
- Progress in pipeline



SHIONOGI

From "Stable Growth" to "Accelerated Growth"



Overseas Business

- **Start of the edaravone business**
 - Entry into the rare disease business
- **Growth of cefiderocol**
 - Further progress in development
 - Strengthen external partnering
- **Launch of ensitrelvir (planned)**
 - Strengthen sales structure following approval



Domestic Business

- **Stabilization of the infectious disease business**
 - Xocova, Xofluza
- **Strengthen sales of new products**
 - Quviviq·Zurzuvae
 - Products marketed by Torii
- **Launch of development pipeline**



HIV Business

- **Application of the equity method to ViiV Healthcare**
 - Stronger commitment to the HIV business
- **Growth of LAI formulations**
 - Cabenuva, Apretude
- **Progress in development of new LAI formulations**
 - Q6M formulation: S-365598 (VH-184)

FY2020

Achieve stable growth together with infectious disease products

FY2025

Overseas Business

Domestic Business


HIV Business

※ Revenue image


Start of the RADICAVA Business in the U.S.

Leveraging the strengths of the established operating company to contribute to patients who have not yet gained access

– Improving Access to Treatment –



–Strengths of RADICAVA Operating Company–





Patient Support in the RADICAVA Business: Three Pillars

Provide comprehensive patient support tailored to each phase from diagnosis through treatment continuation

1


Timely and Reliable Support for Newly Diagnosed Patients



- Raising awareness of the importance of early diagnosis and treatment
- Providing appropriate information to healthcare professionals
- Increasing awareness of RADICAVA among newly diagnosed patients

2


Streamlining Treatment Initiation



- Strengthening proactive and timely patient support
- Reducing time to treatment initiation through faster insurance approvals and seamless pharmacy dispensing
- Enhancing financial support for patients

3

Building a Foundation for Continued Treatment



- Supporting long-term treatment adherence
- Reducing the risk of treatment discontinuation through multiple initiatives
- Providing stage-appropriate support based on data insights



Significant Growth of the U.S. Business and Substantial Strengthening of the Network

Steadily expand the U.S. business by leveraging partnerships with the U.S. Government

- Acquisition of β -lactamase inhibitors
- Strengthened U.S. network
- Initiation of development of new compound S-649228


Accelerate development of S-892216 (LAI formulation for COVID-19)

Launch of S-649228 (cefiderocol + xerubor bactam)

Acquisition of Qpex

Agreement obtained from BARDA/ATI for antiviral drug development*3

Maximization of mid- to long-term value of cefiderocol



U.S. launch of Fetroja

Creation of a novel antibacterial agent effective against gram-negative bacteria including multidrug-resistant strains

Agreement with BARDA*1

Accelerate development of xerubor bactam owned by Qpex


Selection for BARDA Project BioShield*2

- Strengthening U.S. biothreat preparedness through cefiderocol
- Establishment of formulation manufacturing facilities in the U.S.

Domestic Business Enters a Phase of Stable Growth

Drive stable growth through two pillars: Infectious Diseases and QOL Diseases

—Revenue from domestic prescription pharmaceuticals and its breakdown—



—Outlook: Stable growth of the domestic business—

Expansion of the business portfolio

Reducing reliance on volatile infectious disease sales to drive stable domestic growth

QOL disease


Achieve growth centered on new products
Quiviviq, Zarzuvae / SLIT formulations*¹, Corectim, Vtama

Acute respiratory virus infection

Target stable revenue of **40 B yen**
 - Xocova, Xofluza, Rapiacta -

Stable Earnings Contribution from Acute Respiratory Infection Treatments

Promote initiatives to contribute to patients in line with infectious disease trends



—Medical Societies Promoting Appropriate Use of Antiviral Drugs*3,4—

In Japan, early diagnosis and treatment have helped limit the impact of influenza

Early treatment with anti-influenza drugs is essential


Average treatment rate for influenza*5 > **90** %

The same principle applies to COVID-19: early diagnosis and treatment are key

Toward Significant Growth of Two Focus Products in QOL Diseases area

Position the two focus products as growth drivers and pillars of the QOL disease portfolio

—Sales revenue in the QOL disease area—



Zurzuvae (for MDD)

+ **3.5** B yen (YoY)

- Emphasize rapid onset of efficacy and shorter dosing period
- Provide effective individual product information in medical institutions with commercial overlap with Quviviq (~70% organizations)




Quviviq (for Insomnia)

+ **4.1** B yen (YoY)

- Following removal of dosing period restrictions, prescriptions increased significantly
- Highlight longer total sleep time and improved daytime functioning

Torii Pharmaceutical Products to Deliver Growth Exceeding the Previous Year

Growth in the allergen and dermatology areas is expected to drive sales revenue to a record high



Allergen Area*2 + Others + **6.9** B yen YoY

- Cedar cure shipments increased from Oct 2025*3

Dermatology Area + **2.2** B yen YoY


- Corectim and Vtama driving growth
- Full-scale launch of co-promotion (Shionogi+Torii)

*1 FY2025 sales revenue includes SHIONOGI's unconsolidated results for April–August *2 In response to the request from the Japan Fair Trade Commission regarding information blocking related to Actair and Miticure, we are proceeding with careful measures in close coordination with TORII *3 Although limited shipments remain in place, shipment volumes to wholesalers have been increasing steadily

Strong Growth of the HIV Business and Outlook for the Year

Driven by the growth of LAI formulations, HIV sales by ViiV are expected to grow mid- to high single-digit growth in FY2026

Sales Trend Since Launch of LAI Formulations by ViiV



—Treatment—

Sales (CY2025)

£ **1,402** m

Growth (YoY)

+ **42** %



—Prevention—

Sales (CY2025)


£ **439** m

Growth (YoY)

+ **62** %

Development of next Generation of LAI's for HIV Treatment

Longer dosing intervals are expected to drive greater uptake of LAI treatment products



*1 ViiV Healthcare Meet the Management *2 GSK Q3 2025Results

What is S-365598 (VH-184)?

A potential third-generation integrase inhibitor with unique features discovered by SHIONOGI

01

**Potent
antiviral activity**



**Antiviral efficacy comparable to
dolutegravir and cabotegravir**

02

**Distinct resistance profile
Compared with existing agents**



**Retains activity against mutant
viruses resistant to first- and
second-generation INSTIs*¹**

03

**Long-acting durability
Potential for twice yearly dosing**



**A PK profile supporting dosing
intervals up to six months was
presented at CROI 2026*²**

Toward the Realization of the 2030 Vision

- Initiatives in core businesses
- Progress in pipeline



SHIONOGI

Major Pipeline Progress (FY2025)

Infectious Diseases		QOL Diseases with High Social Impact	
Ensitrelvir *1 COVID-19	Post-exposure prophylaxis: Submitted in the US and Europe, approved in Japan Treatment: Submitted in Europe, submitted in Japan (Pediatric patients)	Zuranolon *3 Depression	Approved in Japan
Secutrelvir [S-892216] COVID-19	Oral (Treatment): Phase 2 top-line results obtained LAI formulation (Pre-exposure prophylaxis): Phase 1 FPI	Cantharidin *4 Molluscum contagiosum	Approved in Japan
Cefiderocol *2 AMR (Gram-negative bacterial infections)	Approved in China	Delgocitinib *5 Atopic dermatitis	Submitted in Japan (Addition of lotion formulation)
S-649228 AMR (Gram-negative bacterial infections)	Phase 1 top-line results obtained	Tapinarof *6 Atopic dermatitis (Pediatric patients)	Submitted in Japan (Additional indication)
S-268024 COVID-19 vaccine	Submitted in Japan	Naldemedine *7 Opioid-induced constipation	Approved in China
S-567123 Broadly protective coronavirus vaccine	Phase 1 FPI	S-054502 (Sulthiame) Sleep apnea	Introduced as a new asset (Preparing Phase 2b)
Olorofim Invasive Aspergillosis	Phase 3 LPO	S-606001 Pompe disease	Phase 2 FPI
S-337395 RSV infections	Phase 2b FPI	Zatolmilast Fragile X syndrome	Phase 2/3 top-line results obtained

Zatolmilast: Phase 2/3 trial results (Fragile X syndrome)

Although the primary endpoint was not met, statistically significant improvements were observed across multiple endpoints

—Study overview—

Objective	This study evaluated the efficacy of Zatolmilast over a 13-week treatment period in males with Fragile X syndrome (FXS).	
Study	CNS-301	CNS-204
Primary endpoint	NIH-TCB Crystallized Cognition CCC*1	NRS*2 Language/Communication and Daily Function
Key secondary endpoint	NRS Language/Communication and Daily Function	CGI-I Language/Communication
Design	Multicenter, randomized, double-blind, parallel-group study, placebo-controlled trial	
Target population	Participants diagnosed with Fragile X Syndrome, full mutation	
	For those 18 years to 45	For those ages 9-17
Method of administration	Administer a 25 mg capsule twice daily (BID)	For patients weighing 43 kg or more, 25 mg capsule twice daily (BID). For patients weighing 25-43 kg, 15 mg capsule twice daily (BID).
Number of enrolled participants	Placebo: 58 participants Zatolmilast: 113 participants	Placebo: 52 participants Zatolmilast: 103 participants

—Summary of analysis results—

Endpoints		Group difference vs. placebo at Week 13	
		CNS-301	CNS-204
NIH-TCB	CCC	No significant improvement	No significant improvement
NRS	Language/Communication	Significant improvement*	
	Daily Function		
CaGI-I	Language		
CGI-I	Language	No significant improvement	

*Nominal significance without adjustment for multiplicity. Given the primary endpoint results, this should be interpreted as an exploratory finding

- **Neither trial met its primary endpoint**
- **Several items showed statistically significant improvement in the adult trial**
- **Treatment with zatolmilast was generally well-tolerated, and no new safety concerns were identified**

Zatolmilast: Future Strategy

**Based on the results of the pivotal trials,
the development strategy will be determined in the second half of 2026**

—Ongoing clinical trials—

Fragile X syndrome

Phase 2/3 trials

- Top-line results have been reviewed
- ⇒Additional analyses are planned

Phase 3 trials (Open-label long-term extension)

- LPI achieved
- ⇒Trial ongoing; interim analysis planned

Jordan syndrome

Phase 2 trials

- LPI achieved
- ⇒Preliminary data are expected to be available in FY2026 Q2

Fragile X syndrome

Loss of FMRP*1 due to mutations in the FMR1 gene

Dysregulated local protein translation at synapses

Abnormalities in spine synapses

Symptoms

—Differences in points of action by disease—

Zatolmilast

Enhancement of cAMP signaling through PDE4D*2 inhibition

Improve disease-related cognition and behavior

Act on the core of the disease pathology

Jordan syndrome

PP2A*3 dysfunction caused by PPP2R5D gene mutations
⇒Enhanced dephosphorylation of PKA substrates*4


Symptoms

S-606001 : Mechanism of Action and Development Status

S-606001, a novel treatment approach, achieved FPI in Phase 2 trials*1, with development progressing as planned

—Causes and treatments of Pompe disease—

Pompe disease: A rare disease that is one of the lysosomal storage diseases (incidence: 1 in 22,000 people)




Treatment method	Site of action	Mechanism of action
S-606001 (Under development)	1	Inhibiting GYS1 to suppress glycogen production
ERT*4(Standard treatment)	2	Supplementing GAA to promote glycogenolysis within lysosomes

—Development status—

- March 2025 Phase 1 FPI achieved
—Repeated tablet dose study—
- August 2025 Phase 1 LPO achieved
- **March 2026 Phase 2 FPI achieved**
—Combined testing with ERT—
- Phase 2 LPO is expected in 2027.
For detailed information on Phase 2 trials, please see slide 48
- Scheduled to be launched in 2031 or later

Expanding of the Development Pipeline through M&A

Acquiring promising pipeline assets from former JT pharmaceutical business and Torii



Pipeline Prioritization

While advancing ongoing clinical trials, we plan to review and refocus the pipeline through strategic prioritization

Current status

Undertaking intensive review of each program from scientific, clinical, and commercial perspectives

Decided to add "allergy and immunology" as an additional therapeutic area based on JT pipeline, rare disease area also augmented

Clinical trials actively underway are being progressed to completion

Future actions

- 1 Assessments will incorporate results from forthcoming trials
- 2 All programs, including existing assets, will be subject to prioritization
- 3 The prioritized asset list will be presented at upcoming IR events

R&D Milestones Planned for FY2026 (Infectious disease areas)

The list of applicable assets is planned to be updated on a rolling basis

Topline results: It is the timing of acquisition, and the timing of disclosure will be considered separately

Development products	Target diseases	FY2025	FY2026 1H	FY2026 2H	Target launch timing*1
Ensitrelevir	COVID-19 treatment	Submission	Approval (Europe)		-FY2027
	COVID-19 treatment (Pediatric Ages 6-11)	Submission	Approval (Japan)		
	COVID-19 treatment (Pediatric Ages 0-5)	Phase 3		Phase 3 top-line results	
	COVID-19 PEP	Submission	Approval (US and Europe)		
Secutrelvir [S-892216]	COVID-19 treatment (Oral)	Phase 2	Phase 3 starts		FY2028-2030
	COVID-19 Post-exposure prophylaxis (Injection)	Phase 1		Initiation of Phase 2 IND preparation	FY2031-
S-268024	COVID-19 (JN.1Vaccine)	Submission	Approval (Japan)		-FY2027
S-567123	Broadly protective coronavirus vaccine	Phase 1	Phase 1 top-line results	Phase 2 starts	FY2028-2030
S-337395	RSV infections	Phase 2b		Phase 2b top-line results	FY2028-2030
Olorofim	Invasive Aspergillosis	Phase 3	Phase 3 top-line results	Submission (Europe)	FY2028-2030
Cefideloceol	Pediatric, Gram-negative bacterial infection	Phase 3	Submission (US and Europe)	Approval (US)	-FY2027
S-649228	Gram-negative bacterial infection	Phase 1	Phase 1 top-line results Phase 2 starts		FY2028-2030

*1 This indicates the timing of the initial launch in any country or region where SHIONOGI holds commercialization rights, and is not intended to refer to any specific country or regio

R&D Milestones Planned for FY2026 (QOL disease areas)

The list of applicable products will be updated sequentially, including assets inherited from the former JT Group pharmaceutical business
 Topline results: It is the timing of acquisition, and the timing of disclosure will be considered separately

Development products	Target diseases	FY2025	FY2026 1H	FY2026 2H	Target launch timing*1
Zatolmilast	Fragile X Syndrome	Phase 2/3		Phase 2 Additional analysis results Phase 3 top-line results	FY2028-2030
	Jordan syndrome	Phase 2	Phase 2 top-line results		
S-606001	Pompe disease	Phase 2		Phase 2 LPI	FY2031-
S-054501 [SASS-001] (S-600918 + Combination medicine)	Sleep Apnea with a Central Component	Phase 2	Phase 2 top-line results		FY2028-2030
S-054502 [SASS-002] (Sulthiame)	Sleep Apnea	Phase 2b/3 Preparing	Phase 1 top-line results Phase 2b/3 strats		FY2028-2030
Redasemtide	Epidermolysis bullosa	Phase 2	Phase 2 top-line results	Submission (Japan)	-FY2027
	Acute ischemic stroke	Phase 2b	Phase 2b top-line results		FY2028-2030
Naldemedine	Constipation associated with Parkinson's disease	Phase 2a		Phase 2a top-line results	FY2031-
S-531011	Solid tumor	Phase 1b/2	Phase 2 top-line results		FY2031-
SDS-881	Dementia (AI program for cognitive function testing)	Phase 3	Phase 3 top-line results Submission (Japan)		-FY2027


Shareholder Returns



SHIONOGI

Basic Policy for Cash Allocation

Appropriately allocating expanding cash flows to growth investments and shareholder returns



Sustainable expansion of cash flow

- Stable revenue growth
- Increase in dividends resulting from ViiV becoming an equity-method affiliate



Growth investments



- Continued investment in R&D to support strong in-house drug discovery capabilities
 - Strategic business investments to acquire new growth drivers
- ⇒ Strict adherence to investment decisions aligned with fair value

Shareholder returns




- Aiming to steadily increase dividend amounts in line with business growth
 - Flexible share buybacks implemented in response to investment conditions and market environment
- ⇒ Profit returns adjusted flexibly with consideration of DOE*1 and ROE*2

Shareholder Return

Shareholder return policy through which shareholders can feel our growth

- The year-end dividend is scheduled to be increased by 5 yen per share from the previous dividend forecast to 38 yen per share
- The annual dividend is scheduled to be 71 yen per share, marking the 14th consecutive year of dividend increases
- Planning the 15th consecutive annual dividend increase for FY2026




*1 Effective October 1, 2024, Shionogi has implemented a 3-for-1 stock split of its common stock. Dividends and Treasury stock's Cancellation are calculated based on the assumption that the stock split was implemented at the beginning of the FY2012 *2 Resolution passed on March 30, 2020, and treasure shares cancelled on April 6

*3 Resolution passed on July 31, 2023, and treasure shares cancelled on April 17, 2024

Appendix

Factors Affecting the Increase / Decrease in Operating Profit (vs. Forecast)



• SG&A

- Increased investment in the U.S. business
- Amortization of intangible assets (JT Group pharmaceutical business)
- Increase in expenses due to foreign exchange effects
- Acquisition-related costs for the edaravone business

• Other Income and Expenses

- ① Gain from negative goodwill arising from the M&A of the JT Group pharmaceutical business
- ② An impairment loss reflecting the results of clinical trials for products under development

Revenue Forecast for TORII Pharmaceutical Related Products

(Unit: B yen)

	FY2026		FY2025	Y on Y	
	Forecast Full year	Forecast 1H	Result	Change(%)	Change
Dermatology Area	23.0	11.1	11.7	95.5	11.2
Corectim	9.5	4.9	5.2	83.4	4.3
Vtama	4.2	1.6	1.4	206.8	2.8
Allergen Area・Others	54.6	25.7	28.8	89.6	25.8
TORII Pharmaceutical-related products*	77.6	36.8	40.5	91.3	37.0

***TORII Pharmaceutical-related products**


- ① FY2025 result: September 2025 – March 2026
- ② Change: **+13.2%**
- April 2025 – March 2026: ¥68.5 billion

Changes in Financial Position

Implemented agile financing in connection with growth investments aimed at enhancing mid- to long-term corporate value

■ Total Assets ■ Equity attributable to owners of parent

(Unit: B yen)




Unit: B yen		End of Mar. 2025	End of Mar. 2026	Change
Total Assets	Non-current Assets	676.8	1,266.5	589.7
	Current Assets	858.5	1,310.3	451.8
Equity attributable to owners of parent		1,361.9	1,685.2	323.3
Equity ratio attributable to owners of the parent		88.7%	65.4%	-
Total Liabilities	Non-current Liabilities	43.5	63.2	19.8
	Current Liabilities	129.4	827.4	698.0

In connection with the acquisition of the edaravone business and additional investment in ViiV Healthcare, bridge loans totaling ¥660.0 billion were arranged*1,2

Pipeline: Infectious Diseases


as of May 12, 2026



- Change from January 31, 2026, to May 12, 2026
- S-048133: Preclinical
 - S-365598: Initiated a phase 2b trial (Oral)
 - S-554110: Deleted
 - S-743229: Deleted
 - Baloxavir: Deleted


Pipeline: QOL Diseases with High Social Impact

as of May 12, 2026



Pipeline: QOL Diseases with High Social Impact

as of May 12, 2026



Change from January 31, 2026, to May 12, 2026	
<ul style="list-style-type: none"> • S-462462: Preclinical • Naldemedine (Parkinson's disease with constipation): Initiated a phase 2 trial • Delgocitinib (Atopic dermatitis in pediatric patients): Phase 3 trial • Delgocitinib (Atopic dermatitis): Submitted in Japan • S-151128: Deleted 	<ul style="list-style-type: none"> • S-309309: Deleted • S-222611: Deleted • ADR-001: Deleted • Resiniferatoxin: Deleted

S-606001 : Phase 2 Trial Overview

Design	Multicenter, randomized, placebo-controlled, double-blind trial
Subject	<ul style="list-style-type: none">• Patients with late-onset Pompe disease (18 years of age or older)• Patients who have received enzyme replacement therapy (ERT) for more than two years and whose dosage and administration have not been changed in the past six months.
Duration of administration	<ul style="list-style-type: none">• 52 weeks• Patients who complete the 1-year course of treatment and wish to do so can proceed to a continuation trial.
Key evaluation criteria	<ul style="list-style-type: none">• Change in lung function (%FVC) at 52 weeks
Trial flow	<p>The trial flow diagram illustrates the progression of patients from Week 0 to Week 52. At Week 0, patients receiving ERT are randomized into three groups: S-606001 (high dose) + ERT (top, dark blue bar), S-606001 (low dose) + ERT (middle, light blue bar), and Placebo group + ERT (bottom, grey bar). All groups continue until Week 52. An arrow from the Week 52 point points to a red box containing the text: "For those who wish to participate: Transition to a continued administration trial".</p>

Anti-HIV Drug Released by ViiV

Product name	Formulations	Compounds* ¹	Administrations	Frequency	Indications	CY2025 Sales
Cabenuva	LAI formulations	CAB + RPV	IM injection	Q2M (LA)	Treatment	£ 1,402M
Apretude		CAB	IM injection	Q2M (LA)	PrEP* ²	£ 439M
Dovato	Oral two-drug regimens	DTG + 3TC	Oral	Every day	Treatment	£ 2,678M
Juluca		DTG + RPV	Oral	Every day	Treatment	£ 656M
Tivicay	Oral single agent	DTG	Oral	Every day	Treatment	£ 1,323M
Triumeq	Oral three-drug regimen	DTG+ABC+3TC	Oral	Every day	Treatment	£ 991M

Forward-Looking Statements

- Forecast or target figures in this material are neither official forecasts of earnings and dividends nor guarantee of target, achievement and forecasts, but present the midterm strategies, goals and visions. Official earnings guidance should be referred to in the disclosure of the annual financial report (*kessan tanshin*) in accordance with the rules set by Tokyo Stock Exchange.
- Materials and information provided during this presentation may contain so-called “forward-looking statements”. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements.
- Risks and uncertainties include general industry and market conditions, and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, technological advances and patents attained by competitors; challenges inherent in new product development, including completion of clinical trials; claims and concerns about product safety and efficacy; regulatory agency’s examination period, obtaining regulatory approvals; domestic and foreign healthcare reforms; trend toward managed care and healthcare cost containment; and governmental laws and regulations affecting domestic and foreign operations.
- For products that are approved, there are manufacturing and marketing risks and uncertainties, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials, and failure to gain market acceptance.
- Shionogi disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
- This material is presented to inform stakeholders of the views of Shionogi's management but should not be relied on solely in making investment and other decisions.
- You should rely on your own independent examination of us before investing in any securities issued by our company. Shionogi shall accept no responsibility or liability for damage or loss caused by any error, inaccuracy, misunderstanding or changes of target figures or any other use of this material.
- This English presentation was translated from the original Japanese version. In the event of any inconsistency between the statements in the two versions, the statements in the Japanese version shall prevail.